{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-24-000042","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.555718+00:00","generated_at":"2026-05-31T23:06:56.671643+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aerovate Therapeutics halts Phase 3 PAH trial, launches strategic alternatives review with Wedbush","bullets":["Previously halted enrollment and shut down Phase 3 IMPAHCT trial and long-term extension study.","Now conducting comprehensive review of strategic alternatives to maximize shareholder value.","Engaged Wedbush PacGrow as exclusive strategic financial advisor for the review process.","Alternatives may include acquisition, merger, reverse merger, business combination, or liquidation.","No timetable set and no assurance any transaction will result from the review."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-24-000042","json":"https://secwatch.observer/filing/0001798749-24-000042.json","markdown":"https://secwatch.observer/filing/0001798749-24-000042.md","text":"https://secwatch.observer/filing/0001798749-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000042/0001798749-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874924000042/tmb-20240708x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:06:56.671643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}